$EYEG Target 2.90 for 44% Eyegate Pharmaceuticals (EYEG) said Wednesday it has completed its target enrollment of 21 patients in a mid-stage proof-of-concept study of PP-001 for ocular surface inflammation due to ocular surface diseases, including dry eye.
Topline data from the study are expected to be released in Q4, with
Key stats
About AB Corporate Bond ETF
Home page
Inception date
Dec 13, 2023
Structure
Open-Ended Fund
Dividend treatment
Distributes
Distribution tax treatment
Ordinary income
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
AllianceBernstein LP
Distributor
Foreside Fund Services LLC
EYEG seeks to maximize total return through an actively managed portfolio of corporate bonds. The fund primarily invests in USD-denominated, investment grade fixed income securities of any maturity or duration issued by US and foreign companies. To construct the portfolio, the fund adviser employs a dynamic multifactor approach that considers six broad proprietary categories: value, momentum, size, quality, carry, and volatility. The investment process also takes into account a bonds credit quality and interest rate sensitivity. The fund may invest up to 10% of its net assets in debt securities rated below investment grade. The fund may also hold derivatives, such as options, futures contracts, forwards, or swaps for hedging and non-hedging purposes.
Classification
What's in the fund
Exposure type
Corporate
Stock breakdown by region
Top 10 holdings
EYEG Wedge Breakout + MACD CrossPrice consolidating atop the 200 SMA, and recently the 50 SMA. MACD bull cross, and RSI finding strong support on top of the 50 EMA of the RSI convey upside momentum bias (I find the 50 EMA on the 14 RSI to be very informative, I recommend you try it for yourself). I am looking for price to stay sup
70% profit target EYEGChart is starting to flip bullish on support at LTF's. Will be buying my way down and expecting this gap to close. A little more risk than I normally like to try (8-10%) but 70% run up looking nice and we're seeing lots of tech/bio stock boom lately.
Check my page for a handful of other 50+ % runu
Short the popEven with the fear of biotech companies flying high when they have successful trials, I like the short today. This is a preliminary study that provided very positive news, however the long term price deterioration of the stock points to a pullback and setbacks. This is speculative, thus good luck tr
EYEG - swing idea momentum gap playEYEG had news today so this helped the stock gain visibilty and momentum finance.yahoo.com
RISK / REWARD swing idea and gap play
Analysis:
RSI is at 53 (not oversold) but is in the area of accumulation.
MACD is moving in positive area
Gap Zone hasn't been filled completely
Daytrade idea: over
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.